← The record

RomidepsinIstodax

Recommended OncologyAuthority RequiredSecond-line line 💬 consumer voice

Treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) following at least one prior systemic therapy.

3
Submissions
3 resub
2016–26
On the record
—
ICER range
Cost-min
Cost basis

Decisions on record

3 decisions
  • Meeting Mar 2026 Recommended Relapsed or refractory peripheral T-cell lymphoma
  • Meeting Dec 2017 Deferred Relapsed or refractory peripheral T-Cell lymphoma (PTCL)
  • Meeting Nov 2016 Not recommended Relapsed or refractory peripheral T-cell lymphoma

Access path

3 submissions · public record
  1. TGA registered · Istodax

    TGA label equal than the PBS population

  2. Nov 2016
    Not recommended

    vs no active therapy

  3. Dec 2017
    Deferred
  4. Mar 2026
    Recommended · restricted

    Comparator changed: no active therapy → pralatrexate

  5. PBS listing · Authority Required
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
7.1 The PBAC recommended the Section 100 Efficient Funding of Chemotherapy Program listing of romidepsin for the treatment of patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL). The PBAC considered that despite the uncertainties associated with the clinical comparison presented in the submission, it was likely that romidepsin provided similar health outcomes to pralatrexate in the proposed population.PSD · Mar 2026
7.2 The PBAC noted that PTCL is a heterogenous group of rare cancers, that relapse is common, and that median survival for patients who relapse is low. The PBAC considered there is a high clinical need for additional therapies for R/R PTCL and noted the strong support for romidepsin in the consumer inputs received.PSD · Mar 2026
Economic analysis
6.30 The submission presented a CMA comparing romidepsin with pralatrexate. The key components and assumptions used in the approach are shown in Table 9.PSD · Mar 2026
Table 9: Key components and assumptions of the cost-minimisation approach Component Claim or assumption Clinical claim: effectiveness Effectiveness is assumed to be non-inferior to pralatrexate.PSD · Mar 2026
Clinical claim
6.24 The submission claimed that, compared to pralatrexate, romidepsin is associated with non-inferior effectiveness and different, but non-inferior safety.PSD · Mar 2026
6.25 The ESC agreed with the evaluation that the claim with regard to efficacy was not adequately supported by the data presented.PSD · Mar 2026
Consumer comments
6.5 The resubmission stated (p17) that the analysis referred to in the November 2016 PSD was a comparison of overall survival of PTCL patients given a “treatment career” which includes romidepsin compared to a treatment career which does not include romidepsin, and clarifies that, in the continued absence of comparative studies, “the intention of Section 2 (of the submission) is to present the same external control data comparison as was presented to the …PSD · Dec 2017
6.6 The resubmission was based on one phase II study (0002) and individual patient data sourced from three international databases: 6PSD · Dec 2017

Cost-effectiveness

Cost-minimisation analysis; no ICER calculated

Listing was requested on the basis of a cost-minimisation approach (CMA) versus pralatrexate. PSD · 2026
ICER uncertainEconomic model disputedNo head-to-head trialIndirect comparison

Decision context

PopulationAdult patients with relapsed or refractory peripheral T-cell lymphoma (including AITL, ALCL, PTCL-NOS) who have received at least one prior systemic therapy.

Submission history

3 entries
DecidedOutcomeComparatorICEREvidence
Mar 2026 Recommended · restricted pralatrexate — Single-arm · ORR
Dec 2017 Deferred no active therapy — Single-arm · OS
Nov 2016 Not recommended no active therapy — Single-arm · ORR

Clinical evidence

Trials cited in the PSDs · ClinicalTrials.gov
TrialPhaseNPrimary outcomeStatus
Study 0002 (GPI-06-0002) Ph 2 131 Percentage of Participants With a Complete Response According to the International Worksho… completed

Consumer voice

Dec 2017

One individual provided input via the PBS website Consumer Comments facility, noting the importance of access to medicines for patients.

noting the importance of access to medicines for patients Consumer comments · PSD
access to medicinesunmet need

Similar precedents

By decision profile

Regulatory · TGA

Label equal than PBS population — Both restrict to relapsed/refractory PTCL after at least one prior systemic therapy; PBAC's 'later-line' and 'chemotherapy-refractory' language clarifies but does not narrow the TGA label.

Listed in law

Federal Register of Legislation

PBS listings commencing 1 Jul 2026 were made by these 3 determinations under the National Health Act 1953. A determination covers every listing that commenced that day, so this is the legal instrument in force for the date — not a document naming this medicine. Open it and check.

DeterminationMadeStatus
PB 70 of 2026 11 Jun 2026 In force PDF ↗
PB 73 of 2026 30 Jun 2026 In force PDF ↗
PB 74 of 2026 30 Jun 2026 In force PDF ↗